HedgeChatter

  • Home /
  • Tag Archives

MGNX

MacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

[GlobeNewswire] – ROCKVILLE, Md. — MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and … moreView todays social media effects on MGNXView the latest stocks trending across Twitter. Click to view dashboardSee who MacroGenics is hiring next, click here to view […]

May 7, 2014 Bystocknews , Comments Off on MacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference read more

MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results

[GlobeNewswire] – Clinical study of first DART, MGD006, to commence in Second Quarter 2014 Phase 3 margetuximab gastroesophageal MAGENTA study poised for initiation in second half 2014 moreView todays social media effects on MGNXView the latest stocks trending across Twitter. Click to view dashboardSee who MacroGenics is hiring next, click here to view […]

May 6, 2014 Bystocknews , Comments Off on MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results read more

CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate

[PR Newswire] – SEATTLE, May 6, 2014 /PRNewswire/ — CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company … moreView todays social media effects on MGNXView the latest stocks trending across Twitter. Click to view dashboardSee who MacroGenics is hiring next, click here to view […]

May 6, 2014 Bystocknews , Comments Off on CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate read more

MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014

[GlobeNewswire] – ROCKVILLE, Md. — MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and … moreView todays social media effects on MGNXView the latest stocks trending across Twitter. Click to view dashboardSee who MacroGenics is hiring next, click here to view […]

May 5, 2014 Bystocknews , Comments Off on MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014 read more

MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014

[GlobeNewswire] – ROCKVILLE, Md. — MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and … moreView todays social media effects on MGNXView the latest stocks trending across Twitter. Click to view dashboardSee who MacroGenics is hiring next, click here to view […]

April 28, 2014 Bystocknews , Comments Off on MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014 read more